These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30101114)

  • 1. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.
    Spelta CW
    Vet Med (Auckl); 2015; 6():293-300. PubMed ID: 30101114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
    Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
    Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary Pars Intermedia Dysfunction (PPID) in Horses.
    Kirkwood NC; Hughes KJ; Stewart AJ
    Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
    McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
    J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
    Steel NL; Ireland JL; McGowan CM
    Vet J; 2022 Nov; 289():105899. PubMed ID: 36162625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Case Series of Clinical Signs and Adrenocorticotrophin (ACTH) Concentrations in Seven Horses Transitioning to Pituitary Pars Intermedia Dysfunction (PPID).
    Kirkwood NC; Hughes KJ; Stewart AJ
    Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary pars intermedia dysfunction (equine Cushing's disease) in a Thoroughbred stallion: a single report.
    Hatazoe T; Kawaguchi H; Hobo S; Misumi K
    J Equine Sci; 2015; 26(4):125-8. PubMed ID: 26858577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of pro-opiomelanocortin and encoded peptides, and their processing enzymes in equine pituitary pars intermedia dysfunction.
    Carmalt JL; Mortazavi S; McOnie RC; Allen AL; Unniappan S
    PLoS One; 2018; 13(1):e0190796. PubMed ID: 29309431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary Pars Intermedia Dysfunction and Metabolic Syndrome in Donkeys.
    Gehlen H; Schwarz B; Bartmann C; Gernhardt J; Stöckle SD
    Animals (Basel); 2020 Dec; 10(12):. PubMed ID: 33302557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
    Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
    Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of geographic location, breed, and pituitary dysfunction on seasonal adrenocorticotropin and α-melanocyte-stimulating hormone plasma concentrations in horses.
    McFarlane D; Paradis MR; Zimmel D; Sykes B; Brorsen BW; Sanchez A; Vainio K
    J Vet Intern Med; 2011; 25(4):872-81. PubMed ID: 21745243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
    Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
    J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.